FNY Investment Advisers’s Adverum Biotechnologies ADVM Stock Holding History

FNY Investment Advisers’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-500	Closed	-$26K	–	868
2018 Q2	$26K	Buy	+500	New	+$30.1K	0.01%	334

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Kam Lawrence $97.4M AUM

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FNY Investment Advisers's ADVM Position: Q3 2018 in Review

FNY Investment Advisers sold out of Adverum Biotechnologies (ADVM) in Q3 2018, closing a stake of 500 shares — an estimated $26K sold.

FNY Investment Advisers first reported a position in ADVM in Q2 2018 and held it in 1 quarter. The position peaked at $26K in Q2 2018. 101 funds tracked by Wall St. Rank hold ADVM as of Q3 2018.

FNY Investment Advisers reported no remaining Adverum Biotechnologies position as of Q3 2018 after selling out during the quarter.
FNY Investment Advisers sold 500 Adverum Biotechnologies shares in Q3 2018, an estimated $26K.
FNY Investment Advisers first reported a position in Adverum Biotechnologies in Q2 2018 and held it in 1 quarter.
FNY Investment Advisers's Adverum Biotechnologies position peaked at $26K in Q2 2018.
101 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2018.

Based on FNY Investment Advisers's 13F filing for Q3 2018, filed 29 Oct 2018.